First author here. We solved a 30-year problem in gene therapy by leveraging neonatal immune tolerance. A single AAV vector injection encoding HIV antibodies achieved 89% success in newborns vs 33% in 2-year-olds, with protection lasting through adolescence. This could transform HIV prevention in regions where maintaining regular medical care is challenging. Happy to answer questions about the science or implications.
